国际农药登记的法规框架、通用流程、核心资料与关键概念——帮助您在出海前建立清晰的合规认知。The regulatory frameworks, common workflow, core dossier and key concepts of international pesticide registration — to build a clear compliance picture before you go global.
什么是农药登记，为什么重要What registration is and why it matters
农药登记（Pesticide Registration）是农药原药或制剂进入某一国家／地区市场前，由主管监管机构对其有效成分、产品配方、毒理学、生态毒理学、残留及药效等数据进行的系统性科学评估与行政审批。未获登记的产品不得进口、销售或使用。全球主要市场的监管虽各有差异，但普遍遵循三项原则：以风险评估为核心、以 GLP 数据为基础、以属地申请为前提。理解目标市场的法规框架与评审逻辑，是制定高效、低成本登记路径的第一步。Pesticide registration is the systematic scientific assessment and administrative authorization by a national or regional regulator of an active ingredient or formulated product — covering the active substance, formulation, toxicology, ecotoxicology, residues and efficacy — before it may be imported, sold or used. Unregistered products cannot be placed on the market. While regimes differ across major markets, they share three principles: risk-assessment-led, GLP-data-based, and territory-specific applicant requirements. Understanding the target market's regulatory framework and review logic is the first step toward an efficient, low-cost registration strategy.
从可行性评估到获证维护的六个阶段Six stages from feasibility to upkeep
确定目标国别、登记类型与数据缺口，明确合规路径、周期与预算，形成路线图。Define target country, registration type and data gaps; clarify the pathway, timeline and budget into a roadmap.
开展缺口分析，安排 GLP 毒理、生态毒理、残留、环境归趋与药效试验，必要时桥接已有数据。Gap analysis and GLP toxicology, ecotoxicology, residue, fate and efficacy studies; bridge existing data where possible.
按目标市场格式撰写卷宗，完成翻译、公证认证，标签与 MSDS 符合当地规范。Author the dossier to the target format; translate, notarize, and make labels & MSDS locally compliant.
以当地设立主体或授权代表提交申请，并缴纳规费（如美国 PRIA、欧盟相关规费）。File via a local entity or authorized representative and pay fees (e.g., US PRIA, EU charges).
主管机构开展技术评审，针对质疑进行答复与资料补充，常经历多轮往复。The authority conducts technical review; respond to queries and supply additional data — often over several rounds.
取得登记证后，进行续展、标签变更、扩作与持有人转移等后续维护。After the certificate, handle renewals, label changes, new uses and holder transfers.
登记卷宗通常涵盖的数据模块Data modules a registration dossier typically covers
有效成分鉴别、纯度、异构体、稳定性与剂型等基础数据。Identity, purity, isomers, stability and formulation basics.
急性／亚慢性／慢性毒性、致畸、致癌、致突变，推导 ADI 与 ARfD。Acute/sub-chronic/chronic toxicity, terato-, carcino-, mutagenicity; ADI and ARfD.
对鸟类、鱼类、蜜蜂、土壤生物及陆生／水生生物的影响。Effects on birds, fish, bees, soil organisms and terrestrial/aquatic life.
田间残留试验、加工因子、MRL 推导与膳食风险评估。Field residue trials, processing factors, MRL derivation, dietary risk.
降解、淋溶、吸附、代谢与在环境介质中的行为。Degradation, leaching, adsorption, metabolism and behaviour in the environment.
靶标防效、推荐剂量、作物耐受性与药害评估。Target efficacy, recommended dose, crop tolerance and phytotoxicity.
原药来源等同性（TE）资料，以及符合规范的双语标签与 MSDS。Active-ingredient source equivalence (TE) data, plus compliant bilingual labels and MSDS.
六大目标市场的主管机构、法规框架与实务提示Authorities, frameworks and practical notes for the six markets
主管机构Authority：农业部（MAPA）、国家卫生监督局（ANVISA）与环境署（IBAMA）三方联合评审；所有申请须通过 MAPA 在线系统（SEI/MAPA）提交。Joint review by MAPA (Agriculture), ANVISA (Health Surveillance) and IBAMA (Environment); all applications are filed via MAPA's online system (SEI/MAPA).
法规框架Framework：原药需开展来源等同性评估（Produto Equivalente / Equivalência）；制剂按产品登记。2024 年农药现代化法案中"将非专利产品登记与风险再评估权赋予 MAPA"的条款遭总统否决，新有效成分仍面临 IBAMA/ANVISA 漫长的独立评审。Active ingredients require a source-equivalence assessment (Produto Equivalente); formulations are registered per product. In 2024, the presidential veto of clauses transferring generic-product registration and risk-reassessment powers to MAPA left new active ingredients facing long, independent IBAMA/ANVISA analysis.
💡 要点Note：注重杂质与毒理资料的完整性；关注 SISPA 统一评审系统（计划 2026 年上线）带来的流程变化；等效产品（generic）路径可显著提速。Scrutinize impurity and toxicology completeness; watch the SISPA unified review system (planned for 2026); the generic/equivalent-product route can markedly speed things up.
主管机构Authority：国家农业食品卫生质量服务局（SENASA）主管；部分省份另有附加要求。Led by SENASA (National Agri-Food Health & Quality Service); some provinces impose additional requirements.
法规框架Framework：2025 年《第 458/2025 号决议》及配套手册简化登记流程，尤其利好小众作物／小众用途；允许进口已在原产国登记的农药；本地数据不足时可暂参考原产国 MRL；已采纳 GHS。Resolution 458/2025 and its manual (2025) streamline registration — especially for minor crops and minor uses; import of pesticides already registered in the country of origin is allowed; foreign MRLs may be referenced when local data are lacking; GHS adopted.
💡 要点Note：对"仅出口"产品仅需满足目的地要求并经 SENASA 认证；善用小众作物简易程序与国外数据引用降本提速。Export-only products need only meet the destination's rules and SENASA certification; use minor-crop fast tracks and foreign-data referencing to cut cost and time.
主管机构Authority：农业与畜牧局（SAG）主管农药（plaguicidas）登记。Registration of plaguicidas is led by SAG (Agricultural & Livestock Service).
法规框架Framework：需提交毒理、残留、药效与理化资料，标签须西班牙语；原药需相应支持文件；出口导向下残留与 MRL 合规要求高。Submit toxicology, residue, efficacy and phys-chem data; Spanish labels required; active ingredients need supporting files; export-led, so residue/MRL compliance is strict.
💡 要点Note：高价值水果（车厘子、葡萄、苹果）驱动细分需求，残留限量需与出口市场衔接。High-value fruit (cherries, grapes, apples) drives niche demand; MRLs must align with export markets.
主管机构Authority：环保署（EPA）依《联邦杀虫剂、杀菌剂与杀鼠剂法》（FIFRA）管理；各州可附加登记（如加州 DPR）。The EPA regulates under FIFRA; states may add registrations (e.g., California DPR).
法规框架Framework：登记类型含新有效成分（§3）、终端制剂、Me-Too（实质相似于已登记产品）、进口容许量；依 PRIA 缴纳规费并对应审评时限；受保护数据引用需授权信（Letter of Access, LoA）或数据补偿。Paths include new active ingredient (§3), end-use product, Me-Too (substantially similar to a registered product) and import tolerance; PRIA sets fees and review clocks; citing protected data needs a Letter of Access (LoA) or data compensation.
💡 要点Note：Me-Too／等同路径可大幅缩短周期；州级登记（尤其加州）常需单独办理；务必提前锁定数据授权（LoA）。Me-Too/equivalence routes can cut timelines sharply; state registrations (esp. California) are separate; secure data authorization (LoA) early.
主管机构Authority：风险评估由 EFSA 与 ECHA 承担，欧盟委员会批准活性成分；各成员国主管机关（如德国 BVL、法国 ANSES）负责制剂分区登记。Risk assessment by EFSA and ECHA; the Commission approves active ingredients; member-state authorities (e.g., Germany BVL, France ANSES) handle zonal formulation registration.
法规框架Framework：依 (EC) 1107/2009（植物保护产品）与 396/2005（MRL）；活性成分须先在欧盟层面获批，制剂按北／中／南三区（Zonal）评审、区内互认。Under (EC) 1107/2009 (plant protection products) and 396/2005 (MRLs); active ingredients must first be approved at EU level, then formulations follow zonal (North/Central/South) review with in-zone recognition.
💡 要点Note：原药获批是制剂登记前置；善用分区互认与数据桥接；关注"从农场到餐桌"战略下的农药减量政策走向。AI approval precedes formulation registration; leverage zonal recognition and data bridging; watch pesticide-reduction policy under the Farm to Fork strategy.
主管机构Authority：健康与安全执行局（HSE）下属化学法规司（CRD）负责 GB（大不列颠）登记。HSE's Chemicals Regulation Division (CRD) handles GB (Great Britain) registration.
法规框架Framework：脱欧后建立独立的 GB 登记体系，与欧盟平行但独立；北爱尔兰依《温莎框架》仍遵循欧盟规则；残留限量（GB MRLs）单独制定。A standalone GB regime runs parallel but separate from the EU post-Brexit; Northern Ireland follows EU rules via the Windsor Framework; GB MRLs are set separately.
💡 要点Note：GB 与 EU 可参考但须分别提交；北爱尔兰适用不同安排；标签须英文（及威尔士语如适用）。GB and EU may inform each other but must be filed separately; Northern Ireland differs; labels in English (and Welsh where applicable).
读懂登记路径前必须掌握的术语与机制Terms and mechanisms to master before planning a pathway
证明您的原药与已登记参考来源在杂质谱、工艺等关键指标上等同，即可引用已有毒性等数据——是中国原药企业进入欧美的高性价比路径。Prove your active ingredient is equivalent to a registered reference source on impurities, process, etc., and you can cite existing toxicity data — a cost-efficient route for Chinese AI makers into EU/US.
欧盟将成员国划分为北／中／南三区，由牵头成员国（RMS）评审，区内其他成员国互认，避免重复评审。The EU groups states into North/Central/South zones; the lead member state (RMS) reviews, and others in the zone recognize — avoiding duplicate assessment.
在美欧，后申请者引用前人受保护数据时，须取得数据持有方授权（LoA）或依数据补偿机制付费，是 Me-Too／等同登记的前置条件。In the EU/US, later applicants citing protected data must obtain the holder's Letter of Access (LoA) or pay via data compensation — a prerequisite for Me-Too/equivalence filings.
MRL 决定农产品准入；当某作物／国家无既有 MRL 时，可申请进口容许量（Import Tolerance）以支撑出口。MRLs gate market access; where no MRL exists for a crop/country, an Import Tolerance can be filed to support exports.
多数市场要求申请人在当地设立实体或指定授权代表／代理人，是提交申请合法性的前提。Most markets require an in-country entity or authorized representative/agent — a prerequisite for a lawful filing.
出海登记中最容易被忽视的风险点The risks most often overlooked in outbound registration
各国格式、语言、标准与审评重点不同，须按市场本地化与重新组织。Formats, languages, standards and review focus differ by market; localize and reorganize per target.
中国原药企业常可借 TE 大幅节省试验成本，却因未及时规划而走昂贵的新成分路径。Chinese AI makers can save heavily via TE but often miss it and take the costly new-active route.
巴西新有效成分可长达数年，欧盟活性成分批准亦需数年，须尽早启动。Brazilian new AIs can take years; EU AI approval also takes years — start early.
美国各州（如加州）、阿根廷各省可能有额外登记或备案要求。US states (e.g., California) and Argentine provinces may impose extra registration or filing.
缺 LoA 将导致 Me-Too／等同登记无法引用关键数据而受阻。Without an LoA, Me-Too/equivalence filings stall because key data cannot be cited.
降本增效、提升获批率的务实策略Practical strategies to cut cost, save time and raise approval odds